Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VC004 + itraconazole
- Development stage
- Phase 1
- Lead developer
- Jiangsu Vcare Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VC004 + itraconazole is a drug combination evaluated in clinical pharmacology trials to determine the pharmacokinetic impact of CYP3A4 inhibition on VC004. VC004 is a next-generation small molecule tropomyosin receptor kinase (TRK) inhibitor, specifically targeting TrkA, developed by Jiangsu Vcare PharmaTech for the treatment of locally advanced or metastatic NTRK fusion-positive solid tumors, including those with brain metastases. Itraconazole is a potent inhibitor of the CYP3A4 enzyme. Because VC004 is metabolized by the cytochrome P450 system, this combination is used to assess potential drug-drug interactions and guide dosing recommendations in patients receiving concomitant CYP3A4 inhibitors.
- Other names
- VC004 and itraconazoleVC-004 and itraconazoleVC 004 and itraconazole
02
Targets
CYP51A1 (Sterol 14α-demethylase)PIK3R1 (Phosphatidylinositol 4-phosphate 3-kinase regulatory subunit alpha)STAT3 (Signal Transducer and Activator of Transcription 3)VDAC1 (Hexokinase 2–voltage-dependent anion channel 1 complex)CYP3A4 (Cytochrome P450 3A4)NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on VC004 + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VC004 + itraconazole.